Top Buy Stocks
Sign In
Invest in RARE
$29.51
-1.53 (-4.91%)
At Close: Jul 11, 2025
US FDA declines to approve Ultragenyx's gene therapy for rare genetic disorder
04:45pm, Friday, 11'th Jul 2025
The U.S. Food and Drug Administration has declined to approve Ultragenyx Pharmaceutical's experimental gene therapy to treat a rare genetic disorder, the company said on Friday.
Ultragenyx Receives Complete Response Letter from FDA for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)
04:30pm, Friday, 11'th Jul 2025
Complete Response Letter (CRL) cited specific chemistry, manufacturing and controls (CMC) related observations that are resolvable
Ultragenyx shares plunge after bone disorder trial misses key interim goal
02:28pm, Thursday, 10'th Jul 2025
Shares of Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) slumped around 26% on Thursday afternoon after the company and partner Mereo BioPharma said their late-stage study of setrusumab in osteogenesis i
RARE, MREO Fall as Osteogenesis Study Likely to Continue Till Year End
11:20am, Thursday, 10'th Jul 2025
Ultragenyx Pharmaceutical and Mereo BioPharma shares tumble as investors await key phase III UX143 osteogenesis data now set for release at year-end.
Ultragenyx (RARE) Surges 5.1%: Is This an Indication of Further Gains?
10:20am, Thursday, 10'th Jul 2025
Ultragenyx (RARE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the
Ultragenyx, Mereo Shares Dive As Brittle Bone Disease Drug Misses Early Win
10:06am, Thursday, 10'th Jul 2025
Ultragenyx Pharmaceutical Inc. RARE and Mereo BioPharma Group plc MREO stocks are plunging on Thursday.
Methode Electronics, Ultragenyx Pharmaceutical And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
08:00am, Thursday, 10'th Jul 2025
U.S. stock futures were lower this morning, with the Dow futures falling around 100 points on Thursday.
Ultragenyx and Mereo BioPharma Announce UX143 Phase 3 Orbit Study for Osteogenesis Imperfecta Progressing to Final Analysis
04:05pm, Wednesday, 09'th Jul 2025
Data from Orbit and Cosmic studies expected around the end of the year Data from Orbit and Cosmic studies expected around the end of the year
RARE's GTX-102 Gets FDA's Breakthrough Status for Angelman Syndrome
12:41pm, Monday, 30'th Jun 2025
Ultragenyx Pharmaceuticals' GTX-102 earns FDA Breakthrough status after early data shows sustained progress in Angelman syndrome patients.
Ultragenyx Receives Breakthrough Therapy Designation for GTX-102 in Angelman Syndrome
08:00am, Friday, 27'th Jun 2025
Phase 3 Aspire study enrollment on track to complete in 2025 Aurora study to evaluate GTX-102 in other Angelman syndrome genotypes and ages expected to initiate later this year NOVATO, Calif., June 27
RARE FERRARI BERLINETTAS LINE UP FOR INAUGURAL BROAD ARROW ZOUTE CONCOURS AUCTION
04:03am, Tuesday, 24'th Jun 2025
AUCTION TO FEATURE A 1967 FERRARI 275 GTB/4 FINISHED IN EXTREMELY RARE VERDE PINO | HIGHLY COLLECTIBLE 1970 FERRARI 365 GTB/4 DAYTONA “PLEXI” ONE OF ONLY TWO DELIVERED NEW IN AVORIO | AUCTION TO T
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Friday, 20'th Jun 2025
NOVATO, Calif., June 20, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rar
Ultragenyx (RARE) Up 9.6% Since Last Earnings Report: Can It Continue?
12:36pm, Thursday, 05'th Jun 2025
Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock?
Ultragenyx to Participate at Goldman Sachs 46th Annual Global Healthcare Conference
05:00pm, Tuesday, 03'rd Jun 2025
NOVATO, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for ser
Ultragenyx Underscores Continued Commitment to Rare Disease Innovation with 2024 Impact Report
04:30pm, Wednesday, 14'th May 2025
NOVATO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) released its 2024 Impact Report today, which covers the company's approach to corporate responsibility. T
